COD Research is a leading CRO based in the US and India, specializing in global clinical trials and pharmacovigilance services. With a strong focus on biosimilar trials worldwide, we offer tailored solutions, ensuring quality, compliance, and client satisfaction. Our commitment is to contribute to the advancement of healthcare by delivering reliable and efficient services on an international scale. | We are a technical full-service Contract Research Organization (CRO) that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly integrate with your teams, whether you require functional services for global studies or tailored on-site and off-site support. | We are a technical Full Service CRO that offers end-to-end Clinical Trial Services, complemented by an industry-leading suite of specialized Pharmacovigilance Solutions. Our flexible working models are designed to seamlessly adapt to client requirements, whether you require functional solutions or global studies or tailored on-site and off-site support.
Certmedica International GmbH
Certmedica International GmbH is an innovative healthcare company based in Germany, specializing in the development, manufacturing, and international distribution of scientifically based health products. The company’s portfolio includes high-quality medical devices and dietary supplements designed to support weight management and metabolic health. A key focus of Certmedica’s expertise is the patented ingredient Polyglucosamine L112, which has been investigated in clinical studies and is used in various health products worldwide. By combining scientific expertise, carefully selected raw materials, and strict quality standards, Certmedica develops products that meet high requirements for safety, efficacy, and user acceptance. Certmedica operates internationally and collaborates with distribution partners in numerous markets around the world. In addition to high-quality products, the company supports its partners with scientific expertise, marketing support, and regulatory know-how to successfully develop international markets.
Celltrion, Inc.
A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business. | Celltrion is a leading global biopharmaceutical company dedicated to improving the health and well-being of patients. We have presented a new paradigm to the global biologics market with the launch of the world’s first monoclonal antibody biosimilar. Celltrion will continue to pursue its goal in promoting the health and well-being of patients.
BrevisRefero
BrevisRefero, in partnership with the educational platform BrickMMO, is pleased to be showcasing an ‘Interactive Biologics CDMO Facility Constructed Exclusively from LEGO(R) Bricks’ at it’s booth (1313) at BIO2024. Join us at our booth for an immersive and educational look at the biologics manufacturing like never before! BrevisRefero is a collection of biologics professionals who share a common goal – to improve and support the management of biologics programs from concept to development, GMP manufacturing and into clinical trials for the benefit of patient and sponsor alike. Pulling from more than 100 years of collective technical biotech consulting experience, we work closely with our clients to develop realistic technical and strategic solutions to support the execution and delivery of biologics programs. BrevisRefero also hosts an RFP outsource management platform called RFP>Navigator(R) that simplifies and accelerates Sponsor’s selection of their CDMO partners. | BrevisRefero Corporation is a team of biopharma professionals with a collective 100 years of biotechnology experience who assist Innovator companies to develop and manufacture their large-molecule biologics for clinical trials and commercial markets. The company assists Innovators by partnering with them at the target molecule post discovery stage and walking with them through their product development journey. Ground-level assistive support is provided in all technical aspects of drug development – from analytical methods and process development, through to scale-up and GMP manufacturing, and every aspect in between supporting their CMC program. Utilizing the deep-seated technical experience of BrevisRefero’s full-time consultants, we have developed innovative world-class online technology tools. Our award-winning commercial product RFP>Navigator®as well as our newly developed BioBudget Champion(TM) tool help propel the biopharma industry forward. Whether it is through our technical knowledge, or its application, BrevisRefero is driven to enable Innovators to succeed in their product development journey.
BIO Business Solutions®
BIO Business Solutions is the largest cost-savings purchasing program for the life sciences industry, operated by BIO. We pool the purchasing power of thousands of life sciences companies to negotiate for exclusive pricing and favorable terms on business-critical products, like lab supplies, regulatory services, HR and much more. BIO helped 4,700 life science companies save over $705 million last year alone. | BIO Business Solutions is the largest cost-savings program for the life sciences industry, operated by BIO. We pool the purchasing power of thousands of life science companies to negotiate for exclusive pricing and favorable terms on business-critical products, like lab supplies, cleanroom services, HR and much more. Every year, BIO helps nearly 5,000 companies save over $700 million. | BIO Business Solutions is the largest cost savings program for the life sciences industry, operated by BIO. BIO Business Solutions negotiates significant volume-based discounts, favorable terms, and other benefits on products and services with industry leading suppliers on behalf of BIO members and the members of state and regional biotech associations. Learn more at bio.org/save.
Barrington James
Barrington James are an industry leading, global recruitment business that exclusively serves the Pharmaceutical, Biotechnology and Medical Device sectors. With offices all over the world and hundreds of specialists dedicated to sourcing exceptional talent, we have the capacity and capabilities to deliver world-class recruitment solutions to Life Science companies of all sizes.
Accelsiors Gmbh
Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2025 in the German Pavilion to explore how we can advance your next clinical breakthrough. At Accelsiors CRO, we accelerate biopharmaceutical innovation through a science-driven, patient-centric approach. As a global, full-service CRO, we provide tailored clinical trial solutions designed to de-risk development, optimize timelines, and bring transformative therapies to market faster. With a proven track record in global clinical development, we navigate the complexities of modern drug research—from early-stage clinical development to regulatory approvals and patient-centric trials. Our strategic approach, cutting-edge AI analytics, and deep therapeutic expertise ensure seamless execution and measurable outcomes. | Accelsiors CRO – Science-Driven Clinical Excellence Accelsiors is a global, full-service CRO accelerating clinical development with AI-driven insights, Quality by Design (QbD), and patient-centric solutions. From Phase I to regulatory approvals, we optimize trial execution, ensuring speed, compliance, and success. Visit us at BIO 2026 in the German Pavilion to explore how we can advance your next clinical breakthrough. Let’s discuss how we can accelerate your next clinical breakthrough with Accelerant™, our proprietary Penta-Helix approach—a unique integration of science, patient-centricity, Quality by Design, AI-driven state-of-the-art technologies, and speed with cost-effectiveness at every stage of clinical development.
A2 Healthcare
A2 Healthcare（A2）, a Japan-Taiwan industry leader for clinical development, spearheads global new drug development in Japan from its new US office in Boston area. A2 is the expert for clinical development in Japan and Taiwan. We are interested to invest in our partner’s pipeline for entering drug development, especially for drugs which are already marketed or under development outside of Japan. Clinical Development: A2 is the leading Japanese CRO providing contracted services in the clinical stage. A2 have the capability and experience to support our partners from early to late phases in any therapeutic area, as well as regulatory consultation and submission. A2 is a subsidiary of ITOCHU Corporation which is one of the largest Japanese company and were awarded the Best CRO of the Citeline Intelligence Award 2023. Pipeline Investment A2’s “Pipeline Accelerator Program (PAP)” supports the development of novel drug candidates enter Japanese market by becoming co-developers with the sponsor. In other words, we will invest in your clinical development cost. Through the program, we will enable domestic and foreign biotech startups as well as pharmaceutical companies for entering the Japanese market with a much lower hurdle. | A2 Healthcare Corporation (A2) is a Japan-based full-service CRO and a core member of the ITOCHU Group, one of the largest Japanese trading and investment conglomerates. With approximately 1,300 employees and offices in Tokyo (HQ), Osaka, Taiwan, and Boston, we focus on helping overseas biotech and pharma companies enter and succeed in the Japanese and Taiwanese markets. A2 has been recognized for excellence in clinical operations and partner satisfaction, receiving the Best CRO/CDMO award (2023) and Best Contract Research Organization award (2025) at the Citeline Pharma Intelligence / Citeline Japan Awards. Key points about A2, the ITOCHU Group and our Japan-entry platform: ◆A2 operates J-STEP (Japan Strategic Entry Platform), a one-stop service platform developed together with ITOCHU to support overseas companies across the full product lifecycle in Japan. ◆J-STEP services include: -Japan market and regulatory assessment, PMDA / ICCC strategy, and early pricing and access considerations. -Japan clinical development planning and execution aligned with global programs. -CMO/CDMO coordination and supply chain support tailored to modality. -NDA support, PMS, real-world evidence (RWE) studies, safety, logistics, and MAH services. -Business development and out-licensing support to Japanese pharma companies using ITOCHU’s local network. ◆In 2026, ITOCHU Corporation acquired 100% of CoreMed Co., Ltd., a leading Japanese regulatory and development-strategy consulting firm. ◆CoreMed provides consulting from early development strategy and CMC evaluation through PMDA consultations and marketing authorization applications, supported by a strong network with EU and US regulatory experts. ◆By combining CoreMed’s regulatory and scientific expertise with A2’s clinical operational capabilities, the ITOCHU Group offers integrated “Strategy + Execution” support for Japan, from first regulatory assessment to approval and post-marketing. ◆Therapeutic area experience spans oncology, rare diseases, regenerative medicine and ATMPs, infectious diseases and vaccines, as well as major and specialty indications. ◆Phase I through Phase III, PMS, and RWE studies, including: -Regulatory and clinical strategy development. -PMDA meeting preparation and briefing packages. -Site selection, site management, monitoring, data management, biostatistics, medical writing, safety, and project management. -ICCC coordination and regulatory submissions. -Post-marketing surveillance and observational research. ◆As part of the ITOCHU Group, A2 can also support: -Partnering and out-licensing between overseas biotech and Japanese pharma. -Flexible collaboration models such as co-development, risk sharing, and selective financial support for Japan-focused assets. -Strategic use of ITOCHU’s global networks, including ITC Venture Partners in Silicon Valley and A2’s Boston office. ◆We are looking to connect with: -Overseas biotech and pharma companies seeking a Japan development and regulatory partner. -Companies interested in one-stop Japan market entry using J-STEP. -Partners exploring co-development, risk sharing, or out-licensing opportunities for the Japanese market. Our goal is Your Goal.